Rebecca S. Sippel, MD, associate professor of surgery, University of Wisconsin, Madison, Wisconsin, explains that multiple studies have shown that the incidence and diagnosis of thyroid cancer is on the rise; however, the cause of this increase is largely unknown.
The major risk factors that call for added screening for thyroid cancer are radiation exposure and a positive family history. Unfortunately, the genetics of familial thyroid cancer are complicated and not well understood, Sippel believes. However, it is clear that every person with a first-degree relative that had thyroid cancer should be screened more aggressively.
The large Canadian study that has caused a stir by indicating that mammograms are of no use in women aged 40 to 59 years, and in fact can lead to over-diagnosis of breast cancer, is flawed and misleading
Intensity-modulated radiation therapy (IMRT) improved survival and reduced toxicities compared with conventional radiation treatment in patients with head and neck cancer, according to a recent database analysis.
The phase III SELECT trial of the investigational agent lenvatinib (E7080) met its primary endpoint of progression-free survival (PFS) in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC), according to Eisai Inc., the company that is developing the agent.